ReviewInternational journal of women's health2022
Systemic Lupus Erythematosus Management in Pregnancy.
Review in International journal of women's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.Current rheumatology reviews · 2025Guideline
- Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches.Arthritis care & research · 2026Review
- Mechanism-informed combination therapy and dynamic risk stratification in lupus nephritis: toward durable renal protection.Clinical rheumatology · 2026Review
- Diagnosis to dialogue: Reproductive health conversations and guideline adherence in women with lupus.Lupus · 2026Article
- Anesthesia in systemic lupus erythematosus: a review of key considerations and surgical challenges.Perioperative medicine (London, England) · 2026Review
- Lupus nephritis and kidney transplantation: A narrative review of patient and graft outcomes.World journal of nephrology · 2026Review
- Pregnancy planning in women with rheumatic diseases: an integrated framework for risk stratification and multidisciplinary management.Rheumatology international · 2026Review
- Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study.BMC rheumatology · 2026Article
- Temporal trends in lupus pregnancy over four decades in a referral centre: pregnancy planning and hydroxychloroquine use are associated with improved outcomes.Rheumatology advances in practice · 2026Article
- Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data.Therapeutic advances in drug safety · 2026Article
- Postpartum acquired hemophilia A: immunopathogenesis, diagnostic challenges, and treatment with the CyDRi protocol.Pathology oncology research : POR · 2026Review
- Practical insights for the clinical implementation of the EULAR recommendations for patients with systemic lupus erythematosus.RMD open · 2025Article
- Article
- The impact of early pregnancy disease control in systemic lupus erythematosus patients receiving comprehensive pharmaceutical care on pregnancy outcomes and offspring long-term health.BMC pregnancy and childbirth · 2025Article
- The fourth trimester and challenges for the lupus patient.EULAR rheumatology open · 2025Review
- Role of belimumab in recurrent spontaneous abortions amongst patients with lymphocyte dysfunction: a retrospective case-control study.BMC pregnancy and childbirth · 2025Article
- Article
- Protective Effects of Phycobiliproteins fromPharmaceuticals (Basel, Switzerland) · 2025Article
- Patient Perspectives on Reproductive Health in Systemic Lupus Erythematosus: Exploring Disease Manifestations, Quality of Life, and the Role of Social Support.International journal of women's health · 2025Article
- Relationship of lupus nephritis and pregnancy: A narrative review.World journal of nephrology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) affects reproductive aged women. Issues regarding family planning are an important part of SLE patient care. Women with SLE can flare during pregnancy, in particular those who have active disease at conception or prior history of renal disease. These flares can lead to increased adverse pregnancy outcomes including fetal loss, pre-eclampsia, preterm birth and small for gestational aged infants. In addition, women with antiphospholipid antibodies can have thrombosis during pregnancy or higher rates of fetal loss. Women who have anti-Ro/SSA and anti-La/SSB antibodies need special monitoring as their offspring are at risk for congenital complete heart block and neonatal lupus. Ideally, SLE patients should have their disease under good control on medications compatible with pregnancy prior to conception. All patients with SLE should remain on hydroxychloroquine unless contraindicated. We recommend the addition of 81mg/d of aspirin at the end of the first trimester to reduce the risk of pre-eclampsia. The immunosuppressive azathioprine, tacrolimus and cyclosporine are compatible with pregnancy and lactation, mycophenolate mofetil (MMF)/mycophenolic acid are not. Providers should use glucocorticoids at the lowest possible dose. Methotrexate, leflunomide and cyclophosphamide are contraindicated in pregnancy and lactation. SLE patients on the biologics rituximab, belimumab and abatacept can continue these medications until conception and resume during lactation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.